SAB1300086
Anti-SOST (N-term) antibody produced in rabbit
Ig fraction of antiserum, buffered aqueous solution
Synonym(s):
Anti-CDD, Anti-DAND6, Anti-SOST1, Anti-VBCH
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
Ig fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
mouse, human
technique(s)
immunohistochemistry: 1:50-1:100
indirect ELISA: 1:1000
western blot: 1:100-1:500
NCBI accession no.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... SOST(50964)
Related Categories
General description
SOST (sclerostin) gene codes for the protein sclerostin which is predominantly secreted by the osteocytes. The encoded protein is predominantly expressed in human woven and lamellar bone and mineralizing chondrocytes.
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease.
Immunogen
SOST (NP_079513, 12-42)
This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human SOST.
This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the N-terminal region of human SOST.
Application
Anti-SOST (N-term) antibody produced in rabbit has been used in immunohistochemistry.
Biochem/physiol Actions
Sclerostin regulates bone remodeling in presence of mechanical stimulation. It has an inhibitory effect on the activation of osteoblasts by inducing phosphorylation and degradation of β-catenin. It downregulates bone formation and induces bone resorption. Mutation in this gene causes hyperostosis and leads to Van Buchem disease or sclerosteosis. Increased bone formation and enhanced healing of bone defects are observed upon selective deletion of the SOST gene in mice model. Sclerostin, a glycoprotein, is involved in vascular calcification. It might be associated with cardiovascular disorders.
Physical form
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Asiri R Wijenayaka et al.
The Journal of steroid biochemistry and molecular biology, 164, 369-373 (2015-12-23)
The osteocyte expressed gene SOST encodes sclerostin, a potent negative regulator of bone formation and inducer of bone resorption. We have recently demonstrated that the human SOST gene is positively regulated in response to 1α,25-dihydroxyvitamin D
Abdul Rashid Qureshi et al.
Kidney international, 88(6), 1356-1364 (2015-09-04)
Sclerostin, an osteocyte-derived inhibitor of bone formation, is linked to mineral bone disorder. In order to validate its potential as a predictor of vascular calcification, we explored associations of circulating sclerostin with measures of calcification in 89 epigastric artery biopsies
Francesca Marta Elli et al.
Frontiers in endocrinology, 15, 1296886-1296886 (2024-06-03)
The dysregulation of cell fate toward osteoprecursor cells associated with most GNAS-based disorders may lead to episodic de novo extraskeletal or ectopic bone formation in subcutaneous tissues. The bony lesion distribution suggests the involvement of abnormal differentiation of mesenchymal stem
Yusuke Inagaki et al.
Histopathology, 69(3), 470-478 (2016-02-21)
To assess the immunophenotypic and mRNA expression of sclerostin in human skeletal tissues and in a wide range of benign and malignant bone tumours and tumour-like lesions. Sclerostin expression was evaluated by immunohistochemistry and quantitative polymerase chain reaction (PCR). In
M Kosacka et al.
Advances in experimental medicine and biology, 910, 15-21 (2016-01-29)
Sclerostin, a glycoprotein involved in vascular calcification, could play a role in cardiovascular disorders. Obstructive sleep apnea (OSA) is frequently associated with cardiovascular comorbidities. Thus, in this study we set out to assess the level of sclerostin in patients with
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service